T1	Participants 339 394	patients with intermediate-stage Hodgkin's disease (HD)
T2	Participants 418 518	HD patients in stage I to IIIA with a large mediastinal mass, E stage, or massive spleen involvement
T3	Participants 802 844	146 patients who responded to chemotherapy
T4	Participants 989 1070	11 patients who fulfilled the same inclusion criteria in the subsequent trial HD5
